Biocon share price jumps 8% as Mylan exits in 2026

Biocon stock surges on large Mylan stake sale

Biocon shares jumped more than 6% on Tuesday, with the stock rising as much as 8% in early trade as a large block deal linked to Viatris-owned Mylan came to market. The move put the counter on track for its sharpest single-day surge in about 18 months, according to the report. The stake sale is significant because it removes a known supply overhang from an existing shareholder’s planned exit.

Mylan’s sale is structured as a secondary transaction, which means Biocon will not receive the proceeds. Still, the market reaction highlighted how the removal of a large seller can shift sentiment in the near term. As of writing, the stock was up 7.6% at ₹442.

What Mylan is selling and why it matters

Mylan, part of global healthcare company Viatris, planned to sell up to 9.2 crore shares in Biocon. The proposed sale represents 5.64% of Biocon’s outstanding equity, based on the term sheet cited in the reports. The deal value was pegged at up to ₹3,481 crore.

Multiple reports described the transaction as Mylan’s complete exit from Biocon, ending a long shareholding relationship. One report characterised this as the end of a 17-year partnership. Another report noted that the lock-in period on the shares had expired, enabling Mylan to monetise its investment through a full exit.

Block deal pricing: floor vs. where shares traded

The block deal was launched at a floor price of ₹378.50 per share. This implied a discount of about 7.9% to Biocon’s Monday closing price of ₹410.95 on the NSE. The discounted floor is typical of large stake sales designed to attract institutional demand.

However, the reported execution levels were higher than the floor. Reports on Tuesday said around 9.19 to 9.2 crore shares changed hands at an average price of about ₹400 per share in the pre-open block deal window. That average price suggests the book found demand above the minimum offer level.

Who ran the transaction

Citigroup Global Markets India and Jefferies India were named as the joint bookrunners and brokers for the deal, according to the term sheet referenced in the Reuters report and other media reports. The identity of the buyer was not immediately known in the coverage.

Even without disclosure of counterparties, the scale of the transaction pointed to institutional participation. The shares were absorbed in a single, large trade window, which is designed to minimise disruption to the regular market.

Shareholding snapshot: where Mylan fit in

Mylan held a 5.64% stake in Biocon at the end of FY26, based on shareholding pattern data referenced in the reports. The same 5.64% holding was also described as being in place as of June 2026.

The shareholder base described in the coverage included promoter Kiran Mazumdar-Shaw with around 30% stake, and Glentec International with around 15% stake (as of the period cited). Around 39 mutual funds together held over 15%, insurance companies held more than 6%, and about 3.74 lakh retail shareholders owned roughly 6% as of March 31, 2026. Separately, one report stated that promoters held 44.67% as of June 2026.

How Mylan got the stake in 2026

Reports linked Mylan’s Biocon stake to a corporate transaction completed earlier in 2026. Mylan acquired the 5.64% holding after Biocon completed the acquisition of Mylan’s holding in Biocon Biologics in January 2026. The consideration was described as a mix of a share swap and cash.

As part of that process, Mylan received a preferential allotment of Biocon shares, which later became the subject of the block sale. With the lock-in period reported to have ended, the block deal route enabled Mylan to sell down the entire position in one go.

Deal timeline and settlement dates cited

A term-sheet-based report said the offer opened on 13 July and would close on 14 July. The trade was expected to take place on 14 July, with settlement scheduled for 15 July.

On Tuesday, the market saw the bulk of the stake change hands in the pre-open block deal window, matching the timeline and mechanics typically used for such transactions.

Key figures at a glance

Market impact: removing an overhang without new capital

Because the sale is secondary, the proceeds go to the selling shareholder and not to Biocon. The immediate market relevance was the change in supply dynamics. With Mylan exiting fully, the stock no longer carries the near-term overhang of a known, sizeable seller.

The strong early reaction also reflected how block deals can reset expectations about near-term trading pressure. Still, the reports did not identify buyers, and there were no official statements in the provided text on how the shareholder register changes beyond the sale itself.

What to watch next

The key near-term variables are confirmation of final allotments and any subsequent disclosures about block deal participants, if required by exchange filings. Investors may also track post-transaction shareholding updates to see how the 5.64% stake is redistributed across institutions.

For now, the core outcome described in the reports is clear: Mylan’s sale marks a complete exit from Biocon, and the stock moved sharply higher as the market absorbed the block supply.